New Risk • Aug 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (CA$110k revenue, or US$79k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (CA$43.0m market cap, or US$30.7m). Announcement • Jul 17
Onco-Innovations Limited Initiates ADME Studies for ONC010 Onco-Innovations Limited announced the initiation of key absorption, distribution, metabolism and excretion ("ADME") studies for ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The studies are designed to characterize ONC010's pharmacokinetic and metabolic profile and support the continued IND-enabling development of the program. The initial ADME work is focused on metabolism of the active pharmaceutical ingredient (API) in the ONC010 lead drug candidate. These data are intended to support the Company's broader development strategy by informing manufacturing activities, formulation optimization, toxicology studies and future clinical translation. The studies are expected to contribute to the growing body of preclinical evidence supporting the continued advancement of ONC010 toward clinical evaluation. The ADME studies form part of Onco-Innovations’ broader IND-enabling development program for ONC010, which also includes manufacturing, formulation, safety and regulatory activities intended to support future clinical evaluation. ONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP), a key DNA damage repair enzyme. The program is being developed to exploit vulnerabilities in cancer cells dependent on DNA repair pathways and is intended to provide a differentiated therapeutic approach for patients with difficult-to-treat malignancies. Announcement • Jul 11
Onco-Innovations Completes Analytical Reference Standard Preparation Program For ONC010’s API Onco-Innovations announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient (API) supporting the Company's lead oncology program, ONC010 (the “PNKP Inhibitor Technology”). The reference standard program, which was completed in collaboration with Dalton Pharma Services, included the preparation, purification, analytical evaluation and quality assessment of highly characterized A83B4C63 material intended for use as a reference standard in future analytical testing programs. Reference standards serve as foundational tools within pharmaceutical development and quality control systems, enabling consistent evaluation of identity, purity, potency, stability, impurity profiles and batch-to-batch comparability throughout the development lifecycle. Completion of the program establishes an important analytical benchmark for future manufacturing campaigns and supports the Company's broader strategy of building a comprehensive quality infrastructure for ONC010. The completion of the reference standard program follows several recent chemistry, manufacturing and controls (CMC) achievements within the ONC010 development program, including successful precursor scale-up activities, API manufacturing advancements, analytical method development, chiral purity testing and continued progress toward manufacturing scale-up and regulatory readiness. The reference standard preparation program forms part of a broader analytical development strategy currently underway at Onco-Innovations. Additional activities include analytical method qualification, stability-indicating methodologies, residual solvent testing, impurity profiling, forced degradation studies, formulation characterization and quality control system development. ONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP), a key DNA damage repair enzyme. The program is being developed to exploit vulnerabilities in cancer cells dependent on DNA repair pathways and is intended to provide a differentiated therapeutic approach for patients with difficult-to-treat malignancies. 
